Invesco Ltd. Gossamer Bio, Inc. Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 239,245 shares of GOSS stock, worth $552,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,245

Previous 43,697 447.51%

Holding current value

$552,655

Previous $48,000 512.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$0.78 - $1.44 $152,527 - $281,589	195,548 Added 447.51%	239,245 $294,000
Q1 2025 May 12, 2025	BUY	$0.85 - $1.53 $37,142 - $66,856	43,697 New	43,697 $48,000
Q1 2023 May 12, 2023	SELL	$0.96 - $2.92 $31,129 - $94,686	-32,427 Reduced 56.06%	25,420 $32,000
Q4 2022 Feb 13, 2023	SELL	$1.74 - $12.87 $1.6 Million - $11.8 Million	-918,152 Reduced 94.07%	57,847 $125,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $6.61 Million - $13.6 Million	916,979 Added 1553.68%	975,999 $11.7 Million
Q2 2022 Aug 15, 2022	BUY	$5.97 - $9.97 $55,228 - $92,232	9,251 Added 18.59%	59,020 $494,000
Q1 2022 May 16, 2022	BUY	$8.44 - $12.49 $23,058 - $34,122	2,732 Added 5.81%	49,769 $432,000
Q4 2021 Feb 14, 2022	SELL	$10.12 - $14.07 $54,293 - $75,485	-5,365 Reduced 10.24%	47,037 $532,000
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $24,077 - $43,936	3,321 Added 6.77%	52,402 $659,000
Q2 2021 Aug 17, 2021	BUY	$8.0 - $9.75 $81,160 - $98,913	10,145 Added 26.06%	49,081 $398,000
Q1 2021 May 17, 2021	BUY	$8.63 - $10.94 $235,659 - $298,738	27,307 Added 234.82%	38,936 $360,000
Q4 2020 Feb 16, 2021	BUY	$8.3 - $13.59 $96,520 - $158,038	11,629 New	11,629 $112,000

Others Institutions Holding GOSS

# of Institutions

140

Shares Held

159M

Call Options Held

2.89M

Put Options Held

130K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $217M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account